摘要
目的 探讨伊立替康联合顺铂治疗宫颈癌患者疗效及对血清Bcl-2的影响。方法 将2015年1月-2016年1月在我院收治的124例宫颈癌患者随机分为观察组（62例）和对照组（62例）,观察组采用伊立替康联合顺铂治疗方案,对照组采用紫杉醇治疗方案,比较两组疗效以及对血清Bcl-2的影响。结果 观察组总有效率为80.65%,明显高于对照组的25.81%,差异有统计学意义（P〈0.05）;两组治疗后Bcl-2蛋白表达水平较治疗前均明显降低,且观察组治疗后Bcl-2蛋白表达水平明显低于对照组,差异有统计学意义（P〈0.05）。结论 伊立替康联合顺铂治疗宫颈癌患者有助于降低血清Bcl-2水平,疗效显著,可在临床上推广。
Objective To investigate the efficacy of irinotecan combined with cisplatin in the treatment of patients with cervical cancer and its effect on serum Bcl-2.Methods 124 cases of cervical cancer patients in our hospital from January 2015 to January 2016 were randomly divided into observation group （62 cases） and control group （62 cases）,thc observation group were treated with irinotecan combined with cisplatin,the control group were treated with paclitaxel,the curative effect in two groups and its effect on serum Bc1-2 were compared.Results The total effective rate in the observation group was 80.65%,significantly higher than 25.81% in the control group,the difference was statistically significant （P〈O.05）;The Bcl-2 protein expression levels after treatment in the two groups was significantly lower than that before treatment,and the expression level of Bcl-2 in the observation group after treatment was significantly lower than that in the control group,the difference was statistically significant （P〈0.05）.Conclusion The treatment of irinotecan combined with cisplatin in patients with cervical cancer is helpful to decrease the serum level of Bcl-2 and has a significant effect.which can be popularized in clinic.
出处
《中国当代医药》
2016年第20期75-77,共3页
China Modern Medicine
